Abiraterone Boosts Prostate Cancer Survival
نویسنده
چکیده
Final results of a phase III trial confirm that treatment with abiraterone prolongs overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC) that has progressed after docetaxel therapy. Over a median 20 month follow-up, median OS was 15.8 months for abiraterone (Zytiga®) plus prednisone compared with 11.2 months for placebo plus the steroid (P<0.0001), Karim Fizazi, MD, of the Institut Gustave Roussy in Villejuif, France, and colleagues reported online 18 September 2012 in Lancet Oncology. The findings provide “proof of principle that mCRPC remains androgen-driven,” they wrote, as abiraterone is an inhibitor of CYP17 and thus suppresses androgen synthesis.
منابع مشابه
A Systematic Review of Clinical Practice Guidelines for Castration-Resistant Prostate Cancer
Cancer constitutes a huge burden on societies in countries with any level of economic development. Prostate cancer is the first most diagnosed cancer of men in developed countries and the forth one in developing countries in terms of incidence rate. It is also the third incident cancer of men in Iran along with a prevalence of about 10,000 cases. Castration-resistant prostate cancer (CRPC) is a...
متن کاملAbiraterone: A Review of its Pharmacokinetic, Pharmacodynamic Profile and Clinical Efficacy
Prostate cancer is a common cancer and it causes significant morbidity and mortality in elderly males. Management for metastatic castration resistant prostate cancer has improved tremendously over the last decade with newer agents improving overall survival and quality of life of patients. Until recently, docetaxel was the only agent to show an improvement in overall survival in patients with m...
متن کاملA Systematic Review of Clinical Practice Guidelines for Castration-Resistant Prostate Cancer
Cancer constitutes a huge burden on societies in countries with any level of economic development. Prostate cancer is the first most diagnosed cancer of men in developed countries and the forth one in developing countries in terms of incidence rate. It is also the third incident cancer of men in Iran along with a prevalence of about 10,000 cases. Castration-resistant prostate cancer (CRPC) is a...
متن کاملRe: Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer.
BACKGROUND Abiraterone acetate, a drug that blocks endogenous androgen synthesis, plus prednisone is indicated for metastatic castration-resistant prostate cancer. We evaluated the clinical benefit of abiraterone acetate plus prednisone with androgen-deprivation therapy in patients with newly diagnosed, metastatic, castration-sensitive prostate cancer. METHODS In this double-blind, placebo-co...
متن کاملAbiraterone Acetate: Targeting Persistent Androgen Dependence in Castration-Resistant Prostate Cancer
Abiraterone acetate is the first second-line hormonal agent proven to improve survival in metastatic castration-resistant prostate cancer. It selectively inhibits cytochrome P450 17 (CYP17) α-hydroxylase and cytochrome17,20 (C17,20)-lyase, which are enzymes critical for androgen synthesis. Abiraterone acetate was initially approved in the United States in 2011 after demonstrating a 4-month surv...
متن کامل